NasdaqGS - Delayed Quote USD

Trinity Biotech plc (TRIB)

1.8300 0.0000 (0.00%)
At close: April 26 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. John Gillard President, CEO, Company Secretary & Director 863k -- 1981
Mr. Ronan O'Caoimh Founder & Director 340k -- 1956
Dr. James Walsh Ph.D. Executive Director of Business Development & Executive Director 20k -- 1958
Mr. Des Fitzgerald Interim Chief Financial Officer -- -- --
Mr. Simon Dunne Chief Accounting Officer -- -- 1974
Dr. Gary Keating Ph.D. Chief Technology Officer -- -- 1973
Ms. Eibhlin Kelly Chief Information Officer -- -- 1984
Mr. Colm Molloy Group Director of Human Resources & Culture -- -- 1971

Trinity Biotech plc

IDA Business Park
Bray, A98 H5C8
Ireland
353 1 276 9800 https://www.trinitybiotech.com
Sector: 
Healthcare

Description

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Corporate Governance

Trinity Biotech plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 04, 2024
Trinity Biotech plc Earnings Call

Related Tickers

NDRA ENDRA Life Sciences Inc.
0.2525
+4.21%
 
MYGN Myriad Genetics, Inc.
18.18
+1.11%
 
ISPC iSpecimen Inc.
0.2660
-5.07%
 
MYNZ Mainz Biomed N.V.
0.8181
-4.52%
 
VCYT Veracyte, Inc.
19.31
-0.87%
 
PRPH ProPhase Labs, Inc.
4.7100
-4.85%
 
DRIO DarioHealth Corp.
1.4800
+2.07%
 
RVTY Revvity, Inc.
101.51
-0.57%
 
BIAF bioAffinity Technologies, Inc.
2.3700
-1.66%
 
OPK OPKO Health, Inc.
1.2600
+3.28%